GlassScriptPhysician profile
Raj Vashistha
NPI 1033436977
$4,462.32
in general payments reported to CMS, 2019-2025
22 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $230 · 2021: $130 · 2022: $95.67 · 2023: $2,883 · 2024: $513 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,016 · Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,016.30 |
| Food and Beverage | $1,816.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,599.46 | 2023-2024 | Indigo System |
| Boston Scientific Corporation | $463.98 | 2019-2025 | General - Therapies, Rotablator Rotational Atherectomy System Console Kit |
| Shockwave Medical, INC | $186.15 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $172.49 | 2023-2025 | Symplicity G3, Resolute Onyx |
| E.R. Squibb & Sons, L.L.C. | $171.35 | 2019-2025 | Camzyos, Eliquis |
| Verge Medical, INC. | $143.92 | 2023 | |
| Abiomed | $134.60 | 2019-2025 | Impella |
| Pfizer INC. | $115.47 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $96.61 | 2022-2025 | |
| Amgen INC. | $87.83 | 2020-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $54.08 | 2023-2025 | Amvuttra |
| Medtronic Vascular, INC. | $48.06 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.85 | 2020-2023 | Jardiance |
| Bridgebio Pharma, INC. | $25.93 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $23.49 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.72 | 2025 | Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $17.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.72 | 2019 | |
| Merck Sharp & Dohme LLC | $15.56 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $14.01 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Abbott Laboratories | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Vashistha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.